Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TransMedics Group, Inc.TMDX · Entity 4261 | VP, Global Regulatory Affairs | December 13, 2023 | December 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TransMedics Group, Inc.
Report date December 13, 2023 · Filed December 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,026 |
Reported balance
After 2023-12-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-13 · Exercise / conversion · Acquired 415 · Balance 24,026 |
| Common StockSEC Table I · non-derivative | Direct | 23,820 |
Reported balance
After 2023-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-13 · Sale · Disposed 206 · Balance 23,820 F1: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. |
| Common StockSEC Table I · non-derivative | Direct | 25,452 |
Reported balance
After 2023-12-13 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-12-13 · Exercise / conversion · Acquired 1,632 · Balance 25,452 |
| Common StockSEC Table I · non-derivative | Direct | 23,943 |
Reported balance
After 2023-12-13 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-12-13 · Sale · Disposed 1,509 · Balance 23,943 F1: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. |
| Common StockSEC Table I · non-derivative | Direct | 27,540 |
Reported balance
After 2023-12-13 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2023-12-13 · Exercise / conversion · Acquired 3,597 · Balance 27,540 |
| Common StockSEC Table I · non-derivative | Direct | 25,133 |
Reported balance
After 2023-12-13 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2023-12-13 · Sale · Disposed 2,407 · Balance 25,133 F1: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. |
| Common StockSEC Table I · non-derivative | Direct | 23,348 |
Reported balance
After 2023-12-15 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2023-12-15 · Gift · Disposed 1,785 · Balance 23,348 F2: On December 15, 2023, the reporting person donated 1,785 shares of directly owned common stock to a donor-advised fund, which will use the gifted shares for charitable purposes. F3: Includes 5,685 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-02-27 | Direct | 7,811 |
Reported balance
After 2023-12-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-12-13 · Exercise / conversion · Disposed 415 · Balance 7,811 F4: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.10 · Expires 2033-02-20 | Direct | 7,073 |
Reported balance
After 2023-12-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-12-13 · Exercise / conversion · Disposed 1,632 · Balance 7,073 F5: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 20, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.46 · Expires 2031-02-24 | Direct | 7,813 |
Reported balance
After 2023-12-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-12-13 · Exercise / conversion · Disposed 3,597 · Balance 7,813 F6: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options.
F2: On December 15, 2023, the reporting person donated 1,785 shares of directly owned common stock to a donor-advised fund, which will use the gifted shares for charitable purposes.
F3: Includes 5,685 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020.
F5: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 20, 2023.
F6: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GiftCommon Stock | 1,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · nonDerivative · entry 7 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,348 F2 · kind: On December 15, 2023, the reporting person donated 1,785 shares of directly owned common stock to a donor-advised fund, which will use the gifted shares for charitable purposes. F3 · balance_after: Includes 5,685 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,597 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · derivative · entry 10 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,813 Underlying: Common Stock · 3,597 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,632 | $0.00 Strike: $66.10 | $0.00 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · derivative · entry 9 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,073 Underlying: Common Stock · 1,632 shares Expires 2033-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 20, 2023. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 415 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · derivative · entry 8 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,811 Underlying: Common Stock · 415 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,407 | $75.10 | $180,765.70 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · nonDerivative · entry 6 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,133 F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 3,597 | $38.46 | $138,340.62 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · nonDerivative · entry 5 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,509 | $75.10 | $113,325.90 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · nonDerivative · entry 4 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,943 F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,632 | $66.10 | $107,875.20 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · nonDerivative · entry 3 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 206 | $75.10 | $15,470.60 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · nonDerivative · entry 2 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,820 F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 415 | $16.14 | $6,698.10 |
DisclosureSEC source: 0000950170-23-070835 · ownership.xml · nonDerivative · entry 1 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:36 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,695 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-23-046432 · ownership.xml · derivative · entry 5 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,410 Underlying: Common Stock · 3,695 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:36 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,785 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000950170-23-046432 · ownership.xml · derivative · entry 4 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,496 Underlying: Common Stock · 1,785 shares Expires 2028-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:36 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,708 | $66.52 | $180,136.16 |
DisclosureSEC source: 0000950170-23-046432 · ownership.xml · nonDerivative · entry 3 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,611 F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $66.40 to $66.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 5,685 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:36 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 3,695 | $38.46 | $142,109.70 |
DisclosureSEC source: 0000950170-23-046432 · ownership.xml · nonDerivative · entry 2 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:36 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,785 | $3.22 | $5,747.70 |
DisclosureSEC source: 0000950170-23-046432 · ownership.xml · nonDerivative · entry 1 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 01:01 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 8,705 | $0.00 Strike: $66.10 | $0.00 |
DisclosureSEC source: 0000899243-23-005899 · doc4.xml · derivative · entry 2 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,705 Underlying: Common Stock · 8,705 shares Expires 2033-02-20 F2 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following February 20, 2023 until the option is fully vested on February 20, 2027, subject to continued service. Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 01:01 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 5,685 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005899 · doc4.xml · nonDerivative · entry 1 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,839 F1 · shares: Includes 5,685 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,918 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000899243-22-038601 · doc4.xml · derivative · entry 4 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,105 Underlying: Common Stock · 5,918 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,620 | $63.00 | $102,060.00 |
DisclosureSEC source: 0000899243-22-038601 · doc4.xml · nonDerivative · entry 3 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,154 F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.72 to $63.32, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,695 | $62.24 | $167,736.80 |
DisclosureSEC source: 0000899243-22-038601 · doc4.xml · nonDerivative · entry 2 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,774 F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $61.70 to $62.69, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 5,918 | $38.46 | $227,606.28 |
DisclosureSEC source: 0000899243-22-038601 · doc4.xml · nonDerivative · entry 1 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,149 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000899243-22-038318 · doc4.xml · derivative · entry 8 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,226 Underlying: Common Stock · 1,149 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,977 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000899243-22-038318 · doc4.xml · derivative · entry 7 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,023 Underlying: Common Stock · 3,977 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 567 | $59.00 | $33,453.00 |
DisclosureSEC source: 0000899243-22-038318 · doc4.xml · nonDerivative · entry 5 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,551 F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,149 | $16.14 | $18,544.86 |
DisclosureSEC source: 0000899243-22-038318 · doc4.xml · nonDerivative · entry 4 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 3,046 | $59.00 | $179,714.00 |
DisclosureSEC source: 0000899243-22-038318 · doc4.xml · nonDerivative · entry 3 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,969 F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 3,977 | $38.46 | $152,955.42 |
DisclosureSEC source: 0000899243-22-038318 · doc4.xml · nonDerivative · entry 2 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Dec 13, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,600 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000899243-22-038318 · doc4.xml · derivative · entry 6 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,281 Underlying: Common Stock · 2,600 shares Expires 2028-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| September 02, 2022 Filed Dec 13, 2022 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 2,600 | $3.22 | $8,372.00 |
DisclosureSEC source: 0000899243-22-038318 · doc4.xml · nonDerivative · entry 1 Provost Miriam · CIK 0001773663 · VP, Global Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:47 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000899243-22-007680 · doc4.xml · derivative · entry 1 Provost Miriam · CIK 0001773663 · VP of Global Regl. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 884 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000899243-21-049930 · doc4.xml · derivative · entry 2 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,881 Underlying: Common Stock · 884 shares Expires 2028-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested 25% on the first anniversary of the vesting commencement date, February 20, 2018, and at a rate of 2.0833% each month thereafter until the option is fully vested on the fourth anniversary of the vesting date. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 884 | $3.22 | $2,846.48 |
DisclosureSEC source: 0000899243-21-049930 · doc4.xml · nonDerivative · entry 1 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:34 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,625 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000899243-21-036415 · doc4.xml · derivative · entry 3 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 5,625 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:34 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 3,877 | $31.34 | $121,505.18 |
DisclosureSEC source: 0000899243-21-036415 · doc4.xml · nonDerivative · entry 2 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,554 F1 · kind: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:34 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 5,625 | $16.14 | $90,787.50 |
DisclosureSEC source: 0000899243-21-036415 · doc4.xml · nonDerivative · entry 1 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,206 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000899243-21-031299 · doc4.xml · derivative · entry 2 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,765 Underlying: Common Stock · 2,206 shares Expires 2028-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested 25% on the first anniversary of the vesting commencement date, February 20, 2018, and at a rate of 2.0833% each month thereafter until the option is fully vested on the fourth anniversary of the vesting date. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 2,206 | $3.22 | $7,103.32 |
DisclosureSEC source: 0000899243-21-031299 · doc4.xml · nonDerivative · entry 1 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:45 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000899243-21-008444 · doc4.xml · derivative · entry 1 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-24 F1 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 21:53 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,600 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000899243-20-033750 · doc4.xml · derivative · entry 2 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,971 Underlying: Common Stock · 4,600 shares Expires 2028-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested 25% on the first anniversary of the vesting commencement date, February 20, 2018, and will vest at a rate of 2.0833% each month thereafter until the option is fully vested on the fourth anniversary of the vesting date. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 21:53 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 4,600 | $3.22 | $14,812.00 |
DisclosureSEC source: 0000899243-20-033750 · doc4.xml · nonDerivative · entry 1 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2020 Filed Mar 6, 2020 23:11 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000899243-20-007511 · doc4.xml · derivative · entry 1 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:46 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $3.22 | Not disclosed |
DisclosureSEC source: 0000899243-19-012300 · doc4.xml · derivative · entry 2 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2028-04-05 F2 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · derivative.exercise_date: The option vested 25% on the first anniversary of the vesting commencement date, February 20, 2018, and at a rate of 2.0833% each month thereafter until the option is fully vested on the fourth anniversary of the vesting date. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:46 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $0.92 | Not disclosed |
DisclosureSEC source: 0000899243-19-012300 · doc4.xml · derivative · entry 1 Provost Miriam · CIK 0001773663 · VP of US Regulatory & FDA Rel. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,571 shares Expires 2028-04-05 F2 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · derivative.exercise_date: The option vested 25% on the first anniversary of the vesting commencement date, February 20, 2018, and at a rate of 2.0833% each month thereafter until the option is fully vested on the fourth anniversary of the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.